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PENYARINGAN DAN PENCIRIAN PERENCAT UNTUK AKTIVITI ENZIM 
KITARAN GLIOKSILAT ICL DALAM Candida albicans 
 
ABSTRAK 
Candida albicans adalah patogen oportunis yang menyebabkan kandidiasis pada 
manusia. Laluan metabolik telah diterokai sebagai sasaran antimikrob yang 
berpotensi, iaitu kitaran glioksilat yang membolehkan C. albicans hidup dalam 
keadaan nutrien terhad. Kitaran glioksilat dan enzim utamanya merupakan sasaran 
antikulat yang menarik bagi C. albicans. Dalam kajian ini, pendekatan penyaringan 
alternatif berasaskan sel yang lebih mencerminkan fisiologi sistem manusia, 
digunakan untuk mengenalpasti sebatian yang merencat kitaran glioksilat. Sebatian 
yang dikenalpasti adalah asid kafeik, asid rosmarinik, dan apigenin, yang sebelum ini 
diabaikan, tetapi menunjukkan aktiviti antikulat terhadap C. albicans apabila dikaji 
dalam keadaan fisiologi yang sesuai, dan merencat aktiviti enzim isositrat liase (ICL). 
Kesan senarai sebatian terhadap transkripsi ICL1 menunjukkan keputusan yang 
menarik iaitu asid kafeik dan asid rosmarinik telah meningkatkan transkripsi ICL1. 
Sebaliknya, kesan daripada apigenin menunjukkan penyusutan transkripsi ICL1. 
Analisis in silico bagi struktur molekul untuk menilai persamaan dadah dan 
keselamatan melalui Lipinski’s RO5 dan ADMET juga dipaparkan. Kesimpulannya, 
tiga sebatian yang mensasarkan C. albicans ICL telah dikenalpasti melalui 
penyesuaian saringan dan seterusnya telah digambarkan keadaan fisiologi yang lebih 
tepat. 
  xvi 
SCREENING AND CHARACTERISATION OF INHIBITORS FOR 
GLYOXYLATE CYCLE ICL ENZYME ACTIVITY IN Candida albicans 
 
ABSTRACT 
Candida albicans is an opportunistic pathogen that causes candidiasis in human. 
Metabolic pathways have been recently explored as potential antimicrobial targets, 
for example glyoxylate cycle that enables the C. albicans to survive nutrient-limited 
niches. Glyoxylate cycle and its key enzymes would be an attractive antifungal drug 
target for C. albicans. In this study, an alternative cell-based screening approach that 
better reflect the physiological environment in host system was employed to identify 
lead compounds that inhibit the glyoxylate cycle. The lead compounds identified are 
caffeic acid, rosmarinic acid, and apigenin, which were previously undervalued, but 
demonstrated to have antifungal activity against C. albicans when assayed under 
physiologically relevant conditions, and have inhibitory property on isocitrate lyase 
(ICL) enzyme activity. The lead compounds were further characterized their effects 
on ICL1 transcriptions, which yielded interesting results that caffeic acid and 
rosmarinic acid demonstrated increased ICL1 transcriptions; while apigenin 
demonstrated down-regulation of ICL1 transcriptions throughout the drug exposure. 
The molecular structures were also analysed in silico to assess their drug-likeness 
and safety via Lipinski’s rule-of-five (RO5) and ADMET properties. Taken together, 
three lead compounds targeting C. albicans ICL enzyme were identified by adjusting 
the screening condition to better reflect the physiological condition. 
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CHAPTER 1. INTRODUCTION 
 
Candida albicans and other medically relevant Candida species are mainly 
commensal yeasts commonly found on mucosal surfaces, gastrointestinal and 
genitourinary tracts of human (Pfaller & Diekema, 2010). These yeasts are 
opportunistic pathogens that are most of the time benign, but can be infectious when 
host immune system becomes impaired or an environmental niche becomes available 
(Pappas et al., 2009). The infections caused by Candida species are generally known 
as candidiasis, which can be further classified into superficial infections such as oral 
thrush and vaginal candidiasis, and invasive candidiasis (Perlroth et al., 2007). 
Invasive candidiasis is one of the most common nosocomial invasive infections with 
high mortality rate even with first-line antifungal treatments (Perlroth et al., 2007; 
Pfaller & Diekema, 2010; Mayer et al., 2013).  
 
Choices of antifungal drugs for candidiasis are limited. Those that are in routine 
clinical use include the polyenes, azoles, and echinocandins (Pappas et al., 2009). 
Most of them are either targeting the membrane or the cell wall of fungi. Polyenes 
(Amphotericin B) cause membrane disruption by binding to ergosterol in the plasma 
membrane; azoles inhibit ergosterol synthesis; and the echinocandins inhibit the 
glucan synthesis (Pappas et al., 2009; Chandrasekar, 2011). The limited choices of 
antifungal drugs for candidiasis treatments encourage the search for new antifungal 
drugs, but the progression is slow mainly due to difficulties caused by the limited 
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options of antifungal targets. Firstly, the protein-based targets are prone to the 
emergence of resistant strains. The latest antifungal echinocandins that inhibit the 
β-1,3-glucan synthase for instance, the clinically resistant strains were isolated 
shortly after their launch into the market (Walker et al., 2010; Alexander et al., 2013; 
Fekkar et al., 2013). Secondly, fungi and animals have highly conserved and similar 
cellular pathways and structures further limits the target options for drug discovery, 
for example, the structural similarity between ergosterol in fungi and cholesterol in 
mammals limits the usage of drugs that targeting ergosterol such as polyenes, as it 
leads to toxicity in recipients (Carrillo-Munoz et al., 2006; Cowen, 2008). 
 
 Recently, metabolic pathways have been explored as potential antifungal drug 
targets, due to their importance for the yeast cells to effectively assimilate various 
carbon sources and survive the nutrient-limited host niches (Brock, 2009;     
Mayer et al., 2013). Metabolic pathways such as glycolysis, gluconeogenesis, 
tricarboxylic acid (TCA) cycle, and glyoxylate cycle, are all thought to be important 
for survival and pathogenicity of C. albicans during infection, although their specific 
roles are still remain to be fully explored (Ene et al., 2012; Mayer et al., 2013). The 
potential of glyoxylate cycle as antimicrobial drug target has been studied more than 
other metabolic pathways. The glyoxylate cycle is a modified version of tricarboxylic 
acid (TCA) cycle that bypasses the CO2-generating steps to conserve carbons for 
gluconeogenesis (Lorenz & Fink, 2002; Dunn et al., 2009). The key enzymes for this 
pathway: isocitrate lyase (ICL) and malate synthase (MS), are highly conserved 
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across wide range of organisms such as bacteria, plants, fungi, and nematodes, but 
lack in human systems (Kondrashov et al., 2006; Dunn et al., 2009). Besides, 
glyoxylate cycle also enables the utilization of alternative carbon sources such as 
lactate, ethanol, and glycerol (Lorenz & Fink, 2002; Dunn et al., 2009).  
 
Taken together, the conservation of carbons and utilization of alternative carbon 
sources enables the C. albicans to survive in the glucose-depleted environment in 
most niches of human body systems (Fernández-Arenas et al., 2007;         
Marcil et al., 2008; Dunn et al., 2009). Previous studies suggested that C. albicans 
cells rely on glyoxylate cycle to survive nutrient-limited niches like inside 
macrophages and neutrophils (Fradin et al., 2003; Prigneau et al., 2003; Lorenz et al., 
2004; Fernandez-Arenas et al., 2007; Marcil et al., 2008; Dunn et al., 2009). Besides, 
mutant strains incapable of glyoxylate cycle in mouse model experiments from 
previous studies also indicated that this metabolic pathway is essential for full 
virulence of C. albicans (Lorenz & Fink, 2001). Therefore, glyoxylate cycle is an 
attractive antifungal drug targets to be explored for C. albicans. Glyoxylate cycle has 
also been previously explored as potential antimicrobial drug target in other 
pathogens such as Mycobacterium tuberculosis (Gengenbacher et al., 2010;  
Marrero et al., 2010; Kratky & Vinsova, 2012) and Burkholderia species       
(Van Schaik et al., 2009; Van Acker et al., 2013). More importantly, glyoxylate cycle 
is not conserved in human systems, making it a more promising antifungal target for 
drug discovery in C. albicans with minimal toxicity potentials to recipients. 
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1.1 Objectives of Study 
In this study, glyoxylate cycle or ICL of C. albicans was selected as an 
antifungal drug target for screening and identification of lead compounds from a 
collection of plant reference compounds. Lead compounds are the compounds 
identified via certain screening strategies to posses desired therapeutic or biological 
activity that it binds selectively to the target and elicits the desired functional cellular 
response from the target (Deprez-Poulain & Deprez, 2004; Hefti, 2008). High quality 
lead compounds that are qualify as future drug candidates must have sufficient 
bioavailability to reach the target site, and posses minimal toxicity for clinical trials 
(Hefti, 2008).  
 
The lead compounds in this study are the compounds that survive the cell-based 
alternative screening employed in this study in which the compound has to posses the 
at least the following two criteria: it must be an inhibitor of ICL enzyme that 
selectively binds to the protein in C. albicans; it must not posses any general toxicity 
and detergent or detergent-like properties that can non-specifically reduce the growth 
of C. albicans. In order to identify new lead compounds that inhibit glyoxylate cycle 
which previously was undervalued when tested in physiologically irrelevant rich 
media supplemented with glucose, a minimal defined medium supplemented with 
lactate as a sole carbon source was employed to mimic the host niches environments. 
Besides, the effects of lead compounds on ICL1 expression in C. albicans and their 
drug-likeness and drug safety also were studied. 
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The objectives of this study are: 
i. To identify lead compounds that inhibit C. albicans growth by targeting the ICL 
enzyme activity, 
ii. To study the effects of the identified lead compounds (ICL enzyme inhibitor) on 
ICL1 transcriptions in C. albicans, and 
iii. To predict the drug-likeness and ADMET properties of the identified lead 
compounds by in silico analysis. 
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CHAPTER 2. LITERATURE REVIEW 
 
2.1 Candida albicans and Candidiasis 
C. albicans is opportunistic pathogenic yeast that can cause life-threatening 
invasive candidiasis. Indeed, C. albicans and some other members of Candida 
species are among the most common cause of nosocomial invasive infections with 
mortality rate as high as 50% even with first-line antifungal treatments          
(Pfaller & Diekema, 2010; Mayer et al., 2013). Candida species are the commensal 
yeast virtually present in every individual, reside on mucosal surfaces and the 
gastrointestinal and genitourinary tracts (Pfaller & Diekema, 2010). They are usually 
benign, but can establish infection if immune system of the host is impaired or an 
environment niche becomes available (Finkel & Mitchell, 2011). C. albicans can 
cause two major types of candidiasis in humans: mucocutaneous candidiasis - such 
as oral thrush, vaginal candidiasis, and potentially fatal invasive candidiasis 
(Calderone & Clancy, 2012). 
 
2.1.1 General Characteristics of C. albicans 
C. albicans is a diploid fungus with ability to mate without true sexual cycle. 
Genome sequences of C. albicans revealed many homologues with the model 
yeast Saccharomyces cerevisiae genes involved in sexual cycle, but the former 
lacks critical factors required for meiosis in budding yeast (Brown, 2006). 
Mating of two diploid C. albicans cells result in a tetraploid that divide to yield 
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recombinant diploid progeny (Finkel & Mitchell, 2011). C. albicans is 
polymorphic yeast that can grow either as unicellular yeast, as pseudo-hyphae, 
or as hyphae depending on the encountered environments and state of infections 
(Sudbery et al., 2004; Brown, 2006; Mayer et al., 2013). Further polymorphisms 
include white-opaque cells and chlamydospores, which are spore-like structures 
(Sudbery et al., 2004). Yeast and hyphal forms are usually observed during 
infections with clear functions, but other morphologies are still remain to be 
further studied (Staib & Morschhauser, 2007; Soll, 2009). Besides, ability to 
form biofilms on surface is also an important characteristic of C. albicans. Like 
the biofilms formed by bacterial pathogens, C. albicans biofilms are highly 
resistant to antifungal drugs (Finkel & Mitchell, 2011). Besides, the CUG codon 
is translated as serine in C. albicans, not leucine as usually in other organisms 
(Brown, 2006).  
 
2.1.2 Interactions with Human Hosts 
The interaction between pathogens and their host are complex and dynamic, 
especially for pathogens like C. albicans that can establish recurrent and 
persistent candidiasis in both latent and active forms (Cottier & Pavelka, 2012; 
Tsai et al., 2013). In order to establish an infection, C. albicans cells must adopt 
various strategies to survive the nutrient-limited host niches, host immune 
systems, and proliferate within the host. The host-pathogen interactions of     
C. albicans begins with cell-cell recognition, where the cell wall components of 
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the yeast act as pathogen-associated molecular patterns (PAMPs); while the host 
cells have pattern recognition receptors (PRRs) that can recognize the PAMPs of 
pathogens and activate host immune defense system (Tsai et al., 2013). 
Furthermore, different sets of PRRs can be expressed on different cell types 
within host, plus phenotypic switching and polymorphism may also change    
C. albicans cell wall PAMPs within distinct host niches (Tsai et al., 2013).  
 
2.2 Carbon Metabolism of C. albicans 
In order to survive and grow in a wide variety of host niches, C. albicans must 
be able to assimilate various carbon sources to generate new biomass, where it 
assimilates six-carbon sugars (glucose) via the glycolytic pathway, and two-carbon 
compounds such as lactate via glyoxylate cycle and gluconeogenesis. Besides, the 
yeast must rapidly regulates its metabolic pathways as it encounters new 
micro-environments within the host, depends on the carbon sources available. The 
metabolic pathways of glycolysis, gluconeogenesis, tricarboxylic acid (TCA) cycle, 
and glyoxylate cycle are summarized in Figure 2.1. 
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Figure 2.1. Metabolic pathways of glycolysis, gluconeogenesis, TCA cycle, and 
glyoxylate cycle. Gluconeogenesis is the enzymatically reversible pathway of 
glycolysis catalysed by the same enzymes except phosphofructokinase (glycolysis) 
and fructose-1,6-bisphosphatase (gluconeogenesis). Glyoxylate cycle (dashed arrow) 
is a modified TCA cycle that bypasses the CO2-generating steps to conserve carbons, 
differentiated from TCA cycle by the two key enzymes: ICL and MS. Adapted from 
Lorenz & Fink (2002). 
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2.2.1 Glycolysis and Gluconeogenesis 
Glycolysis is a central and highly conserved carbon metabolic pathway consists 
of the anaerobic conversion of glucose to pyruvate, plus the net production of 
two molecules of ATP. Pyruvate generated by glycolysis may be either 
anaerobically fermented to ethanol, or enter the TCA cycle under aerobic 
conditions. The genes encoding glycolytic enzymes and their expressions in 
yeast pathogens like C. albicans have all been identified and studied extensively 
at transcriptional and proteomic levels (Swoboda et al., 1994; Fradin et al., 2003; 
Barelle et al., 2006; Kusch et al., 2007). Generally, glycolysis is repressed 
during the early infection when glucose may not be readily available, and is 
expressed later during tissue colonization and invasion (Lorenz & Fink, 2002; 
Barelle et al., 2006). 
 
Gluconeogenesis is the reverse form of glycolysis, which allows the synthesis of 
glucose-6-phosphate from non-sugar compounds when glucose is not readily 
available. Gluconeogenesis may be an important source of carbohydrates 
building block monomers (glucose) for cell wall synthesis in C. albicans under 
certain conditions during infection (Eschrich et al., 2002). Since 
gluconeogenesis and glycolysis are enzymatically reversible, they share most of 
the enzymes; only two key enzymes are specific to gluconeogenesis: 
fructose-1,6-bisphosphatase (FBP1) and phosphoenolpyruvate carboxykinase 
(PCK1). Gluconeogenesis might be crucial to C. albicans virulence as mutant 
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strains with deletion of either the genes encoding the key enzymes display 
reduced virulence (Barelle et al., 2006; Ramirez & Lorenz, 2007). The 
regulation of gene expression involved in gluconeogenesis in C. albicans has 
been previously studied at both the transcriptional and proteomic levels 
(Eschrich et al., 2002; Lorenz et al., 2004; Barelle et al., 2006;          
Kusch et al., 2007; Ramirez & Lorenz, 2007). 
 
2.2.2 Tricarboxylic acid (TCA) Cycle and Glyoxylate Cycle 
The TCA cycle also known as the citric acid cycle or Krebs cycle, is one of the 
central metabolic pathways taken place in mitochondria of C. albicans. In the 
aerobic utilization of glucose, pyruvate generated by glycolysis is oxidatively 
decarboxylated into acetyl-CoA, which is completely oxidized to carbon dioxide 
and water in the TCA cycle. Besides, TCA cycle also generates intermediates for 
biosynthesis of amino acids, fatty acids, and for gluconeogenesis       
(Lorenz & Fink, 2002). The expression of TCA cycle enzymes and their 
enzymatic activities has been studied previously at the proteomic level in      
C. albicans (Kusch et al., 2007). 
 
The glyoxylate cycle is a modified TCA cycle that bypasses the carbon 
dioxide-generating steps to conserve carbons for gluconeogenesis, where they 
are incorporated into new molecules of glucose (Dunn et al., 2009). In 
glyoxylate cycle, two-carbon compounds such as ethanol, lactate, and acetate 
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can be assimilated and incorporated into glucose via gluconeogenesis. Therefore, 
glyoxylate cycle enables growth of C. albicans under glucose-depleted 
conditions but two-carbon compounds are available as carbon sources. The key 
enzymes that specific to glyoxylate cycle are isocitrate lyase (ICL) and malate 
synthase (MS), which are functionally conserved in wide variety organisms 
across kingdoms, including fungi, plants, and bacteria, but not in mammals 
(Kondrashov et al., 2006; Dunn et al., 2009). 
 
2.3 Pathogenicity of C. albicans 
Candidiasis established by C. albicans are supported by combination of various 
pathogenicity mechanisms, which include virulence factors such as: polymorphism, 
adhesins and invasins, phenotypic switching, biofilm formation, hydrolytic enzymes 
secretion; and fitness attributes such as: rapid adaptation to environmental pH 
fluctuations, metabolic flexibility, and stress response (Nicholls et al., 2011;   
Mayer et al., 2013).  
 
2.3.1 Polymorphism 
C. albicans is a polymorphic yeast that can grows as unicellular budding yeasts, 
pseudo-hyphae, hyphae, white opaque cells, and chlamydospores depending on 
the environments it encounters (Sudbery et al., 2004; Mayer et al., 2013). The 
polymorphism of C. albicans is complex and dynamic, affected by wide variety 
of environmental factors such as pH, temperature, nutrient availability, and 
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quorum sensing molecules (Mayer et al., 2013). The formation of 
pseudo-hyphae and hyphae by C. albicans from unicellular yeast (Figure 2.2) is 
affected by a numbers of factors, such as starvation, serum, temperature, carbon 
dioxide, and quorum sensing (Albuquerque & Casadevall, 2011; Sudbery, 2011).  
 
Quorum sensing is the communication tool of C. albicans among themselves and 
with other microbes surrounding them in order to successfully survive in a niche 
(Hall et al., 2011). The quorum-sensing molecules are secreted into the 
environment, generally to control processes that involve cell-cell interactions 
and the formation of multicellular structures such as hyphae and biofilm 
formation in C. albicans (Hogan, 2006). The well-studied quorum sensing 
molecules that influence the morphology of C. albicans include farnesol, tyrosol 
and dodecanol (Hornby et al., 2001; Chen et al., 2004; Hall et al., 2011). 
Previous studies suggested that polymorphism of yeast to hyphal growths 
(Figure 2.2) are important for pathogenicity of C. albicans and potentially be 
antifungal drug targets (Jacobsen et al., 2012). The hyphae form of C. albicans 
has been proven to be more invasive than that of the unicellular yeast from, 
which is believed to be involved in dissemination during infections            
(Berman & Sudbery, 2002; Jacobsen et al., 2012). 
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Figure 2.2. Unicellular yeasts, pseudohyphae, and hyphae of C. albicans. A: 
pseudophyphae is resembling the true hyphae but have a constriction at the bud neck; 
B: unicellular yeasts appear similar to Saccharomyces cerevisiae diploid cells, some 
with budding daughter cells; and C: hyphae have a narrower and uniform 
filamentous germ tubes. Adapted from Sudbery (2011). 
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2.3.2 Adhesions and Invasions 
The cell-cell adhesions among C. albicans cells, with other microorganisms and 
host cells, as well as to abiotic surfaces, are mediated by a set of cell surface 
glycoproteins, called adhesins (Garcia et al., 2011). One of the best studied 
adhesins should be glycosylphosphatidylinositol (GPI)-linked cell surface 
glycoproteins, which are also among the most important adhesins that are 
up-regulated during various candidiasis (Sundstrom, 2002; Cheng et al., 2005; 
Albrecht et al., 2006; Naglik et al., 2011). Besides, these adhesins were also 
shown to contribute to biofilm formation in C. albicans (Nobile et al., 2008).  
 
In terms of invasions, C. albicans employs two strategies: inducing endocytosis 
by the host cells, and active penetration, in order to invade the host cells and 
tissues (Wachtler et al., 2012; Mayer et al., 2013). For induced endocytosis, a set 
of cell surface proteins called invasins that bind to the host cell surface ligands 
such as E-cadherin and N-cadherin, are expressed by C. albicans cells to induce 
the engulfment by the host cells (Phan et al., 2005; Wachtler et al., 2012). There 
are two identified invasins: Als3 and Ssa1, which induce endocytosis by the host 
cells via binding to E-cadherin (Sun et al., 2010).  
 
In contrast, active penetration is initiated by hyphae of C. albicans, which 
penetrate by physical force into the host cells and tissues (Dalle et al., 2010). 
The molecular mechanisms for active penetration is still remain to be fully 
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studied. However, it has been suggested that extracellular hydrolytic enzymes 
such as proteases and lipases play important roles to facilitate the active 
penetration into the host cells and tissues (Naglik et al., 2003;         
Wachtler et al., 2012). 
 
2.3.3 Extracellular Hydrolytic Enzymes 
Upon adhesion to host cell surfaces C. albicans secretes extracellular hydrolytic 
enzymes to enhance nutrient uptake and invasions by active penetration    
(Naglik et al., 2003; Wachtler et al., 2012). There are three types of extracellular 
hydrolytic enzymes being secreted by C. albicans during invasions: proteases, 
phospholipases, and lipases.  
 
Secreted aspartyl proteases (SAPs) are extracellular proteases encoded by a gene 
family of ten members, namely SAP1 to SAP10; SAP1 to SAP8 are extracellular; 
whereas SAP9 and SAP10 are cell surface proteins (Naglik et al., 2003;  Taylor 
et al., 2005; Albrecht et al., 2006). These genes are differentially regulated 
depend on different growth stages of C. albicans-host interaction. However, the 
expression of other SAPs have been detected in various clinical infections, for 
instance expression of SAP7 has been detected in some clinical sample of human 
oral thrush, and SAP8 has been detected at high level in vaginal candidiasis 
(Naglik et al., 2003).  
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Phospholipases of C. albicans consist of four different classes of proteins, 
namely A, B, C, and D, but only five members of class B are extracellular and 
involve in pathogenicity via disruption of host cell membranes          
(Mayer et al., 2013). Mutant strains with deletion of any of these five genes have 
been shown to have attenuated virulence in mouse model invasive infection 
(Theiss et al., 2006). Extracellular lipases of C. albicans is the least studied 
family of extracellular hydrolytic enzymes but the contribution of extracellular 
lipases to virulence has been proposed as they were observed to be differentially 
activated during the yeast-to-hyphae transition, in mouse model of invasive 
candidiasis, and from patient specimens (Hube et al., 2000; Stehr et al., 2004, 
Schofield et al., 2005). Furthermore, extracellular lipases from C. albicans have 
been reported to exhibit cytotoxic effects on macrophages and liver cells via the 
production of reactive oxygen species (Paraje et al., 2008; Paraje et al., 2009). 
 
2.3.4 Biofilm Formation 
Many candidiasis established due to their ability to adhere to abiotic surface and 
form biofilm on implanted medical devices (Donlan & Costerton, 2002;  
Douglas, 2003). Biofilms is a unique form of growth for C. albicans, where the 
heterogeneous cells are encased in extracellular matrix (ECM) and shielded from 
host immunity and antimicrobial agents (Figure 2.3) (Chandra et al., 2012).  
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Figure 2.3. Scanning Electron Microscope (SEM) of an in vivo C. albicans 
biofilm. Unicellular yeasts, pseudohyphae, and hyphae are encased within the ECM 
in the biofilm. Adapted from Finkel & Mitchell (2011). 
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Implanted medical devices such as venous catheters, urinary catheters, 
pacemakers, and artificial joints, are commonly used with more than ten million 
recipients worldwide each year (Kojic & Darouiche, 2004; Taff et al., 2012). 
Medical device-associated candidiasis are difficult to be eradicated, and like 
bacterial biofilms, Candida biofilms are highly resistant to antifungal drugs 
compared to their planktonic counterpart, even without accumulation of 
drug-resistance genes (Nett et al., 2011; Taff et al., 2012). Therefore, surgical 
replacement of implanted devices is mostly the only option for treatment of 
medical device-associated candidiasis. 
 
Biofilm formation of C. albicans starts when the planktonic yeast cells attach to 
virtually any abiotic surfaces (implanted medical devices), followed by 
proliferation and mixed growth of unicellular yeast cells, pseudohyphae, and 
hyphae across the surface, ECM accumulates and shields the encased cells from 
host immunity attacks and high level of drug resistance is acquired as the biofilm 
matures (Figure 2.4) (Finkel & Mitchell, 2011). One important feature of 
Candida biofilm is ECM, which encases the yeast cells together, controlling 
disaggregation, and shields the yeast cells from antifungal drugs and host 
immune system (Taff et al., 2012). The main component of ECM in Candida 
biofilm is β-1,3-glucan, where the genes related to glucan synthesis such as 
FKS1 (glucan synthase gene), are up-regulated during formation of biofilms 
(Nett et al., 2007).  
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Figure 2.4. Biofilm development of C. albicans. Attachment: unicellular yeast cells 
adhere to abiotic surface; initiation: cell-cell adhesion and proliferation; maturation: 
mixed growth of yeast cells, pseudohyphae, and hyphae in ECM; dispersal: some of 
the cells detach from biofilm and migrate to new locations. Adapted from          
Fox & Nobile (2012). 
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Another important feature of C. albicans biofilm that contributes to resistance 
and recurrent candidiasis is presence of a population fraction called persister 
cells (Fauvart et al., 2011). Persister cells are population fraction in the biofilm 
that are metabolically dormant and highly resistant to antifungals (Lewis, 2010). 
As described in Figure 2.5, antifungal drugs and host immune system kills most 
of the encased cells in the biofilm, except the persister cells which repopulate the 
biofilm with new population fraction of persister cells after discontinuation of 
antifungal therapy (Al-Dhaheri & Douglas, 2008). 
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Figure 2.5. C. albicans biofilm and persister cells. Antimicrobial therapy and host 
immune defence system eliminates almost all the cells in the biofilm except persister 
cells which are highly resistance. The persister cells exit from dormancy and 
repopulate the biofilm after the therapy discontinued. Adapted from Lewis (2010). 
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2.3.5 Metabolic Flexibility 
Carbon is central and fundamental element for survival and growth of all living 
things. The carbon sources for C. albicans in host are likely to be glucose, lipids, 
proteins, amino acids and other alternative carbon sources. In order to survive 
and establish candidiasis, C. albicans must be able to utilize these carbon 
sources and adapt rapidly to changes in nutrient availability (Mayer et al., 2013). 
For instance, C. albicans in blood stream can utilize glucose, which is rich in the 
blood via glycolysis and TCA cycles, but the cells engulfed by phagocytic cells 
would suffer from starvation due to glucose-depletion environment inside the 
macrophages (Brock, 2009).  
 
In response to glucose-depletion, C. albicans initially switches from glycolysis 
to gluconeogenesis, and activation of glyoxylate cycle in order to utilize lipids 
and amino acids available inside the phagocytic cells (Lorenz et al., 2004). In 
other host niches, C. albicans also often encountered glucose-depletion niches 
and utilized host proteins, amino acids, lipids, and phospholipids as alternative 
carbon sources via glyoxylate cycle. It was previously shown that metabolic 
plasticity of C. albicans is not only crucial for survival and growth, but also 
affect pathogenicity (Brown, 2006; Ene et al., 2012; Mayer et al., 2013). 
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2.4 Current Drugs for Candidiasis 
The antifungal therapy for candidiasis varies substantially depends on the 
Candida species, clinical situation of the patients, and the susceptibility of the isolate 
to specific antifungal drugs (Pappas et al., 2009). Currently approved antifungal 
drugs for the treatment of candidiasis generally comprises four major categories: the 
polyenes (amphotericin B), the azoles (fluconazole, itraconazole, voriconazole, and 
posaconazole), the echinocandins (caspofungin, anidulafungin, and micafungin), and 
flucytosine. The current antifungal drugs for candidiasis and their mechanisms are 
summarized in Table 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
